Galderma Laboratories, L.P. has announced that the US Food and Drug Administration (FDA) has approved Mirvaso® (brimonidine) topical gel, 0.33%

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

New User Registration
 
 
 
 
 
 
 
 
 
Please indicate that you agree to the Terms of Service *
*Required field